|
BETABLOCKERS MAY EXACERBATE REBOUND HYPERTENSION FOLLOWING CLONIDINE WITHDRAWAL, SO IF CLONIDINE IS TO BE WITHDRAWN THEN BETABLOCKERS SHOULD BE DISCONTINUED SEVERAL DAYS BEFORE CLONIDINE
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS ENHANCE THE VASOCONSTRICTOR EFFECTS OF THE DRUG
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MAOIS CAN CAUSE SEVERE HYPOTENSION WHEN GIVEN CONCURRENTLY
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
MYOCARDIAL DEPRESSION MAY BE POTENTIATED
|
MYOCARDIAL DEPRESSION MAY BE POTENTIATED
|
CONCURRENT USE WITH BETABLOCKERS PRODUCES ADDITIVE NEGATIVE INOTROPIC EFFECTS
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETA-2 SYMPATHOMIMETICS LIKE RITODRINE
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
CO-ADMINISTRATION OF CETACHOLAMINE DEPLETOR,SUCH AS RESERPINE, MAY RESULT IN HYPOTENSION AND /OR MARKED TACHYCARDIA WHICH MAY PRODUCE VERTIGO, SYNCOPE OR POSTURAL HYPOTENSION
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
BETABLOCKERS MAY CAUSE BRADYCARDIA & HYPOTENSION
|
BETABLOCKERS MAY CAUSE BRADYCARDIA & HYPOTENSION
|
BETABLOCKERS MAY CAUSE BRADYCARDIA & HYPOTENSION
|
INCREASED RISK OF VASCULAR OCCLUSION
|
INCREASED RISK OF VASCULAR OCCLUSION
|
INCREASED RISK OF VASCULAR OCCLUSION
|
INCREASED RISK OF VASCULAR OCCLUSION
|
INCREASED RISK OF VASCULAR OCCLUSION
|
INCREASED RISK OF VASCULAR OCCLUSION
|
REDUCED ANTIHYPERTENSIVE EFFECT OF BETA BLOCKERS
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
POSSIBLE POTENTIATION OF BRADYCARDIA, SINUS ARREST AND AV BLOCK
|
CIMETIDINE INCREASES ITS PLASMA CONCENTRATION AND HENCE BIOAVAILABILITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|